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Camptothecin (CPT) is a cytotoxic quinoline alkaloid which inhibits the DNA enzyme Topoisomerase-I (Topo-I) and has shown remarkable anticancer activity in preliminary clinical trials. The major limitation is its low solubility and high adverse reaction. In 
the studied work, we performed molecular docking of CPT derivatives against Topo-I and developed the quantitative structure activity relationship (QSAR) model for anticancer activity screening. For QSAR, we used CPT and other anticancer drugs with its 
IC50 values. We used a total of forty seven anticancer drugs as training set and eight compounds as test set and thirty derivatives of CPT as query set. Total of fifty two chemical descriptors were used for the quantitative data calculation. Only four showed good 
correlation with the experimental activity. Forward feed regression method was used for development of multiple linear regression (MLR) QSAR model. Model showed acceptable regression coefficient (r 2) 0.89 (i.e., 89% of correlation) and cross validation 
coefficient (rCV2) 0.86 (i.e., 86 % of prediction accuracy). After drug likeness test, ten compounds namely, MSB3a, MSB3b, MSB19, MSB22L, MSB22M, MSB22O, MSB22R, MSB25D, MSB37G and MSB39D, showed promising predicted anticancer 
activity and drug likeness properties. Out of ten, only six compounds namely, MSB19, MSB22L, MSBM, MSB22O, MSB22R and MSB37D indicate two times more activity than the parent CPT compound. In molecular docking studies, all the identified 
active CPT derivatives showed high binding affinity with Topo-I. QSAR study indicates that connectivity index, electron affinity, mol.wt. & ether group count highly contribute to inhibitory activity of CPT derivatives. These results can offer useful references 
for directing the molecular design of Topo-I inhibitor with improved anticancer activity.
Abstract
 Introduction
Method 
Retrieval of  Crystal structures
3D crystal structure of DNA Topo-I protein (PDB: 1T8I) and chemical compounds were retrieved from PDB (www.rcsb.org) and PubChem 
databases respectively.
Cleaning, Optimization & molecular docking of CPT derivatives
3D structure of CPT derivatives were designed and optimized through ChemBioOffice software. Molecular structures of target protein Topo-I 
and chemical molecules were prepared and docked through Scigress Explorer v7.7 (Fujitsu). Molecular docking was performed to find out the 
binding affinity or molecular interaction energy (kcal/mol) of docked compounds calculated by using PMF scoring scheme. Lowest energy of 
docked molecule indicates high binding affinity with the target protein. Binding pocket of docked CPT active derivatives were studied for 
selection radius 3Å.
Multiple linear regression QSAR modeling for anticancer activity targeting Topo-I
Calculation of 2D and 3D molecular chemical descriptors for QSAR modeling by using forward feed multiple linear regression method and 
drug likeness study (Lipinski et. al., 2001) was done through Scigress Explorer v7.7. The model was constructed with 45 compounds in the 
training set, which was validated by the remaining molecules in the test set. We employed ‘leave-one-out’ cross validation procedure.
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Conclusion
• The docking results of 10 CPT derivatives showed that the active residues of Topo-I binding pocket are hydrophilic and polar in nature. 
• There was a significant correlation between binding affinity (docking energy) and the experimental IC50. 
• Moreover, Asp-533, Arg-364, Gln-421, and Lys-374 are the key residues in the binding pockets responsible for molecular binding with CPT 
derivatives. 
• QSAR model for CPT derivatives was successfully developed to understand the interaction factors governing its activity. Results indicate that 
the developed QSAR model is robust and have good predictive capability for anticancer activity targeting Topo-I. 
• The QSAR results indicate that hydrogen bonds highly contribute to inhibitory activity, followed by hydrophobic and electrostatic factors. 
• The results of QSAR were consistent with the molecular docking.
Results
• MLR method was employed to generate a linear relationship that correlates changes in the computed steric and electrostatic potential fields 
with changes in the corresponding experimental values of the training compounds activity (IC50). 
• Docking results showed that all the active CPT derivatives docked on Topo-I with high binding affinity.
• 2D contour maps of CPT derivatives were compared with the crystal structure of Topo-I complex (PDB: 1T8I).
• Docking results of 10 CPT derivatives showed that the important residues of Topo-I active pocket are hydrophilic and polar.
• Asp-533, Arg-364, Gln-421, & Lys-374 are the key residues in the binding pockets responsible for molecular binding with CPT derivatives.
• QSAR results indicate that connectivity index, electron affinity, molecular weight, & ether group count highly contribute to inhibitory activity 
of CPT derivatives on Topo-I, followed by H-bond, hydrophobic and electrostatic factors.
Predicted logIC50 (nM) (C) =
-0.591058 x Connectivity Index (order 1, standard) (H) 
+3.0669 x Electron Affinity (eV) (N)
+0.0312332 x Molecular Weight ( Z)
-1.00655 x Group Count (ether ) (AH)
-5.42856 
[rCV2=0.869478; r2=0.899566]
Table 1. Comparison of experimental and predicted in 
vitro  activity (IC50) data calculated through developed 
QSAR model based on correlated chemical descriptors.
Chemical Sample Exp. 
IC50 
(nM)
Exp. 
log 
IC50 
(nM)
Pred . 
log  IC50 
(nM)
Connectivity 
Index (order 
1, std.)
Electron 
Affinity 
(eV)
Molecular 
Weight
Group 
Count 
(Ether)
1(CPT) 677 2.831 2.753 12.525 1.534 348.357 0
2 Topotecan 1046 3.020 3.097 13.346 1.499 378.384 0
32 (methylenedioxy) 416 2.619 2.472 17.868 1.538 504.541 2
33 (methylenedioxy) 27 1.431 1.390 13.991 1.580 392.367 2
34 (methylenedioxy) 15 1.176 1.372 13.991 1.574 392.367 2
35 (methylenedioxy) 150 2.176 2.204 14.419 1.577 426.812 2
36 (methylenedioxy) 61 1.785 1.553 14.419 1.563 407.382 2
38 (methylenedioxy) 210 2.322 2.418 17.475 1.597 489.527 2
39 (methylenedioxy) 160 2.204 1.973 15.957 1.609 445.431 2
41 (methylenedioxy) 140 2.146 2.210 17.475 1.561 486.483 2
42 (methylenedioxy) 100 2.000 2.388 18.406 1.461 519.553 2
44 (ethylenedioxy CPT) 300 2.477 2.386 18.868 1.417 532.595 2
45 (ethylenedioxy CPT) 11 1.041 1.169 14.919 1.401 420.421 2
46 (ethylenedioxy CPT) 190 2.279 2.121 18.475 1.408 517.580 2
48 (ethylenedioxy CPT) 180 2.255 2.470 18.475 1.552 514.537 2
50 (ethylenedioxy CPT) 600 2.778 2.565 19.406 1.426 547.607 2
MSB3a  
 
 
2.516 12.525 1.457 348.357 0
MSB3b 2.517 12.525 1.458 348.357 0
MSB19 2.112 13.957 1.481 392.410 1
MSB 22L 1.846 15.439 1.539 438.436 2
MSB 22M 1.849 16.350 1.430 466.490 2
MSB 22O 0.977 16.905 1.420 480.516 3
MSB 22R 0.977 15.939 1.537 452.463 2
MSB 25D 0.536 10.298 1.118 245.349 0
MSB 37G 1.279 18.963 1.464 526.501 2
MSB39 D 1.559 14.419 1.565 407.382 2
S.
No.
Compound DNA Topo-I 
protein PDB ID
Docking 
energy
(Kcal/mol)
Binding pocket residues (4Å) Atoms of 
involved in 
docking
Residues 
involved in 
docking
Length of 
H-bond 
(Å)
No. of 
H-bond
1 CPT 1T8I -73.43
PHE—361, GLY-363, ARG-364,  HIS—367, LYS-493, 
THR-498, , ALA-499,  LYS-532, ASP-533 - - - -
2 TOPOTECAN 1T8I -77.60
PHE—361, GLY-363, ARG-364, HIS—367, LYS-493, 
THR-498, , ALA-499, LYS-532, ASP-533 - - - -
3 MSB 3a 1T8I -78.28
PHE-361, GLY-363, ARG-364, HIS-367, LYS-493, 
ALA-499, LYS-532, ASP-533
H8356-O23 ASP-533 2.137 1
4 MSB 3b 1T8I -83.44
PHE-361, GLY-363, ARG-364, HIS-367, LYS-493, 
ALA-499, LYS-532, ASP-533
H6954-O22 ARG-364 2.177 1
5 MSB 19 1T8I -81.50
ASN-352, GLU-356, ARG-364, ARG-488, LYS-532, 
ASP-533, ILE-535,, HIS-632, GLN-633, ALA-715, 
THR-718
H8045-O21 ARG-488 1.912 1
6 MSB  22L 1T8I -90.71
GLU-356, PHE-361,  GLY-363,  ARG-364, HIS-367,  
LYS-374,   LYS-425, LYS-493, THR-498, ALA-499, 
LYS-532, ASP-533, SER-534
H8356-O23 ASP-533 1.928 1
7 MSB 22M 1T8I -94.15
PHE-361, ARG-362,  GLY-363,  ARG-364, LYS-374, 
GLN-421,  LYS-425, LYS-493, THR-498, ALA-499, 
THR-501, LYS-532, ASP-533
H7045-O23 LYS-374 2.169 1
8 MSB 22O 1T8I -92.51
GLU-356, PHE-361,  GLY-363,  ARG-364, HIS-367,  
LYS-374, ILE-420, GLN-421, SER-423,   LYS-425, 
LYS-493, THR-498, ALA-499, LYS-532, ASP-533
H7437-O32
H8356-O23
GLN-421
ASP-533
2.137
2.076
2
9 MSB 22R
1T8I
-94.96
GLU-356,  PHE-361, PHE-361,  GLY-363,  ARG-364, 
HIS-367, THR-498, ALA-499, LYS-532, ASP-533, 
SER-534
H8356-O23 ASP-533 2.036
1
10 MSB 25D 1T8I -79.62
ARG-488, LYS-532, ASP-533, ILE-535, LYS-587, 
ARG-590, ASN-631, HIS-632, GLN-633, THR-718
H8044-N7 ARG-488 2.016 1
11 MSB 37G 1T8I
-110.36 PHE-361, ARG-362,  GLY-363,  ARG-364, LYS-374,  
GLN-421,  ARG-488, LYS-532, ASP-533, ILE-535, 
HIS-632, GLN-633, ALA-715, THR-718
H8354-O23 LYS-532 2.005 1
12 MSB 39D 1T8I -82.62
ASN-352, GLU-356, PHE-361,  GLY-363,  ARG-364, 
HIS-367,  LYS-374,  GLN-421, LYS-425,  ALA-499, 
LYS-532, ASP-533
H8356-O23
H6954-O18
ASP-533
ARG-364
1.816
2.061
2
Table 2. Details of binding affinity of CPT derivatives and its binding pocket residues docked on Topo-I.
Matrix used for QSAR modeling= d x n
Chemical descriptors used for forward feed multiple linear regression(d)=52 
No. of reference/known drugs (n) = 45
No. of test compounds used for the prediction of activity = 4
Figure 1. Multiple linear regression curve for CPT QSAR 
modeling showing comparison of experimental logIC50  and 
predicted logIC50. 
Figure 2.  Docking score of CPT derivatives with anticancer 
human target DNA Topo-I.
Figure 4. Molecular insight of CPT derivatives docked on human anticancer target DNA Topomerase-I showing binding site 
pocket residues comparable to Camptothecin and Topotecan.
Camptothecin (CPT) (control) docked on human anticancer 
target enzyme DNA Topoisomerase-I (Topo-I) (1T8I) with 
docking score -73.43 kcal/mol.
Topotecan (control) docked on human anticancer target Topo-
I (1T8I) with docking score -77.60 kcal/mol.
CPT derivative (3a MSB) docked on Topo-I anticancer 
receptor with docking score -73.28 kcal/mol.
CPT derivative (3b MSB) docked with high affinity on Topo-I 
with docking score -73.44 kcal/mol.
CPT derivative (19 MSB) docked with high affinity on Topo-I 
with docking score -81.50 kcal/mol.
CPT derivative (22M MSB) docked with high affinity on Topo-I 
with docking score -94.15 kcal/mol.
CPT derivative (22L MSB) docked with high affinity on Topo-I 
with docking score -90.71 kcal/mol.
CPT derivative (22O MSBDK) docked with high affinity on Topo-I 
with docking score -92.51 kcal/mol.
CPT derivative (22R MSBDK) docked with high affinity on 
Topo-I with docking score -94.96 kcal/mol.
CPT derivative (25D MSB) docked with high affinity on Topo-I 
with docking score -79.62 kcal/mol.
CPT derivative (27G MSB) docked with high affinity on Topo-I 
with docking score -110.36 kcal/mol.
CPT derivative (39D MSB) docked with high affinity on 
Topo-I with docking score -82.62 kcal/mol.
Figure 3. Superimposition of most complementary 
conformation of CPT and Topotecan.
 In the current era, one of the leading disease related causes of death of the human population in the world is cancer and it is predicted to 
continue to be the same in the coming years (Gibbs JB, 2000).
 Topotecan is presently indicated as a second-line therapy for advanced ovarian cancer and small-cell lung cancer. Irinotecan is approved for 
use in the treatment of advanced colorectal cancer, both as first-line therapy in combination with 5-FU and as salvage treatment in 5-FU 
refractory disease, including 9-AC, 9-NC, GI-147211, exatecan mesylate, and karenitecin. A lot of CPT analogs have been synthesized and 
evaluated, several 3D QSAR studies of CPT were reported from laboratories, but failed in clinical trials (Carrigan SW et al., 1997).
 So far Yoon et al. (2003) have successfully developed the QSAR model for CPT derivatives other then present study targeting serum esterase 
and designed a new, easily activated SN-38 prodrug for anticancer activity (Yoon KJP et al., 2003). 
 In the studied work, we successfully build the predictive multiple linear regression QSAR model for anticancer  activity, targeting Topo-I by 
using CPT and other known anticancer drugs. In order to further understand the inhibition mechanism of CPT derivatives and to guide structural 
modification in CPT analogs, a QSAR and molecular docking studies of CPT derivatives was performed.
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